Holen Sie sich die Stockscreener-App
203.77
0.66%
-1.4097
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BDX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$205.18
Offen:
$205.97
24-Stunden-Volumen:
38,058
Relative Volume:
0.02
Marktkapitalisierung:
$58.05B
Einnahmen:
$21.84B
Nettoeinkommen (Verlust:
$1.68B
KGV:
34.96
EPS:
5.8293
Netto-Cashflow:
$2.67B
1W Leistung:
+4.56%
1M Leistung:
+7.95%
6M Leistung:
+16.14%
1J Leistung:
-13.05%
1-Tages-Spanne:
$203.07
$206.37
1-Wochen-Bereich:
$193.60
$206.99
52-Wochen-Spanne:
$162.29
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Vergleichen Sie BDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
203.76 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ISRG
Intuitive Surgical Inc
|
586.39 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
ALC
Alcon Inc
|
79.82 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
251.25 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
42.66 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
Is Becton Dickinson and Company (BOX) stock a top hedge fund pickJuly 2025 Pullbacks & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
What to Expect From Becton, Dickinson and Company's Next Quarterly Earnings Report - Barchart.com
Stifel raises Becton Dickinson stock price target to $215 from $210 - Investing.com UK
Stifel raises Becton Dickinson stock price target to $215 from $210 By Investing.com - Investing.com South Africa
The Truth About Becton Dickinson and Co (BDX): Quiet Healthcare Giant, Loud Money Moves - AD HOC NEWS
Becton, Dickinson and Company (BDX) Announces Blackout Period fo - GuruFocus
Becton Dickinson announces temporary blackout period for 401(k) plan stock fund - Investing.com
Becton Dickinson & CoOn Dec 30, Bd 401(K) Plan to Enter Blackout Period Due to Waters DealSEC Filing - TradingView — Track All Markets
Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst - Benzinga
Mcdaniel Terry & Co. Sells 74,357 Shares of Becton, Dickinson and Company $BDX - MarketBeat
Becton, Dickinson and Company $BDX Shares Bought by D.A. Davidson & CO. - MarketBeat
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $207 - 富途牛牛
BD Marks Milestone with First Phasix Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - Finviz
RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target - Insider Monkey
Becton, Dickinson and Company $BDX Shares Sold by Lazard Freres Gestion S.A.S. - MarketBeat
An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 40% Undervalued - Yahoo Finance UK
The Truth About Becton Dickinson & Co (BDX): Quiet Giant Or Sleeper Stock You’re Sleeping On? - AD HOC NEWS
Becton Dickinson announces temporary blackout period for 401(k) plan stock fund By Investing.com - Investing.com Nigeria
Becton, Dickinson and Company (NYSE:BDX) Shapes Global Healthcare - Kalkine Media
Becton Dickinson EVP sells $120,000 in company stock - MSN
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Feld, Becton Dickinson EVP, sells $14509 in stock By Investing.com - Investing.com Nigeria
Feld, Becton Dickinson EVP, sells $14509 in stock - Investing.com
BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment - Quantisnow
BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec - Quantisnow
Banque de Luxembourg S.A. Boosts Holdings in Becton, Dickinson and Company $BDX - MarketBeat
Franklin Lakes OKs affordable housing on Becton Dickinson site - Bergen Record
DAVENPORT & Co LLC Has $120.08 Million Position in Becton, Dickinson and Company $BDX - MarketBeat
Becton Dickinson (BDX): Evaluating Valuation After New Immunology Partnership with University of Pennsylvania - Yahoo Finance
BD faces hernia mesh lawsuit from Tela Bio - MassDevice
Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly - Benzinga
Trust Co. of Vermont Lowers Stake in Becton, Dickinson and Company $BDX - MarketBeat
Medical device maker Becton Dickinson sued over alleged hernia mesh monopoly - Reuters
BD and Penn Institute Ink Collaboration to Advance Immunotherapy - Yahoo Finance
IV Dressing Market Set for Dynamic Rise with Key Players Becton, - openPR.com
Is Becton Dickinson and Company stock a safe haven asset2025 Momentum Check & Accurate Trade Setup Notifications - ulpravda.ru
Becton, Dickinson and Co (NYSE:BDX) Shows High Technical and Pattern Scores Ahead of Potential Breakout - Chartmill
Becton Dickinson Faces Antitrust Suit Over Hernia Mesh Products - Bloomberg Law News
BECTON DICKINSON & CO ($BDX) CEO 2025 Pay Revealed - Quiver Quantitative
Form DEF 14A BECTON DICKINSON & CO For: Dec 12 - StreetInsider
Becton Dickinson, University of Pennsylvania partner on human immune profiling - TipRanks
Becton, Dickinson, University of Pennsylvania to Collaborate on Immune Profiling - 富途牛牛
BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry - Finviz
Inside the 1,000-person immune study aiming to decode disease defenses - Stock Titan
Insider Sell: Michael Garrison Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
BECTON DICKINSON Executive Sells Shares Under Trading Plan - TradingView — Track All Markets
VP Garrison Sells 629 ($123.3K) Of Becton Dickinson & Co [BDX] - TradingView — Track All Markets
Can Becton Dickinson and Company (BOX) stock reach $200 price targetBear Alert & Verified Momentum Stock Alerts - Bollywood Helpline
The Magnificent 7 Are So Yesterday. These Are AI’s Next Big Winners - Forbes
RBC Capital Raises Becton Dickinson (BDX) Price Target to $210 | - GuruFocus
RBC Capital Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $210 - 富途牛牛
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):